The main aim of this study is to check for side effects from TAK-954 and whether it speeds up the recovery of gastrointestinal function after small-bowel or large-bowel resection surgery. Participants will be treated with TAK-954 before surgery and up to 10 days after surgery.
The drug being tested in this study is called TAK-954. In this study TAK-954 is being administered presurgery to evaluate if it can enhance the recovery of GI function postsurgery in participants undergoing open or laparoscopic-assisted partial small- or large-bowel resection. In addition, some participants will also receive TAK-954 postoperatively to evaluate if there is an additional benefit when this drug is administered both pre and post-surgery. The study will enroll approximately 180 participants. Participants will be equally randomized into one of the three remaining parallel treatment arms- which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need). All participants will be given intravenous infusion preoperation and daily postoperation until return of upper and lower GI function or for up to 10 days. This multi-center trial will be conducted in the United States and Germany. The overall time to participate in this study is up to 100 days. Participants will be treated with the study drug for up to 10 days after surgery or until return of GI function post-surgery (whichever occurs first).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
209
TAK-954 placebo-matching intravenous infusion.
TAK-954 intravenous infusion.
Time From End of the Surgery to Resolution of Upper and Lower Gastrointestinal (GI) Function Postsurgery as Assessed by the Investigator
The time from end of surgery to tolerance of solid food, without first occurrence of vomiting or clinically significant nausea for 1 calendar day after a solid meal (upper GI function) and first spontaneous bowel movement (lower GI function), whichever occurred later up to 10 days postsurgery was observed. Kaplan-Meier survival analysis method was used.
Time frame: Day 1 (surgery) up to Day 10 postsurgery
Time From the End of the Surgery (Time the Incision is Closed) Until Ready for Discharge as Assessed by the Investigator
The time from the end of surgery (time the incision is closed) until ready for discharge was defined as time from end of surgery until the participant presented effective intestinal transit (spontaneous bowel movement), tolerated solids without vomiting or clinically significant nausea for 1 calendar day after a solid meal, had satisfactory pain control with oral analgesics, and was medically stable/free of complications. Kaplan-Meier survival analysis method was used.
Time frame: Day 1 (surgery) up to Day 24
Time From the End of Surgery Until the Discharge Order is Written
Kaplan-Meier survival analysis method was used.
Time frame: Day 1 (surgery) up to Day 24
Time From the End of Surgery to Discharge From Hospital
Kaplan-Meier survival analysis method was used.
Time frame: Day 1 (surgery) up to Day 24
Time From End of Surgery to Tolerance of Solid Food as Assessed by the Investigator
The time from end of surgery to tolerance of solid food was defined as intake of solids without vomiting or clinically significant nausea for 1 calendar day after a solid meal. Kaplan-Meier survival analysis method was used.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
University of South Alabama Medical Center
Mobile, Alabama, United States
Keck School of Medicine
Los Angeles, California, United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
University of California Irvine Medical Center
Orange, California, United States
Parkview Community Hospital Medical Center
Riverside, California, United States
University of Colorado
Aurora, Colorado, United States
University of Miami Leonard M. Miller School of Medicine
Miami, Florida, United States
Center for Colon & Rectal Surgery - Altamonte Springs
Orlando, Florida, United States
Cleveland Clinic Florida
Weston, Florida, United States
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States
...and 15 more locations
Time frame: Day 1 (surgery) up to Day 10 postsurgery
Time From End of Surgery to First Spontaneous Bowel Movement as Assessed by the Investigator
The time from end of surgery to first spontaneous bowel movement was defined as a stool not induced by the use of enemas or laxatives. Kaplan-Meier survival analysis method was used.
Time frame: Day 1 (surgery) up to Day 10 postsurgery
Percentage of Participants With Postoperative Gastrointestinal Dysfunction (POGD) >= 5 Days as Assessed by the Investigator
Participants unable to tolerate solid foods, take anything by mouth, or requiring insertion or reinsertion of nasogastric (NG) tube at or after 5 days post-surgery. Percentages are rounded off to whole number at the nearest single decimal. Stratified Miettinen and Nurminen approach was used for analysis.
Time frame: Day 1 (surgery) up to Day 10
Percentage of Participants Requiring Insertion of Nasogastric (NG) Tube Postsurgery
Participants who required insertion of NG tube postsurgery for drainage and symptom relief in case of persistent nausea and vomiting postsurgery were observed. Percentages are rounded off to whole number at the nearest single decimal. Stratified Miettinen and Nurminen approach was used for analysis.
Time frame: Day 1 (surgery) up to Day 24 postsurgery (10 days of treatment period postsurgery plus 14-day observation period post last dose for recurrence of symptoms)
Time From End of Surgery to First Flatus
Kaplan-Meier survival analysis method was used.
Time frame: Day 1 (surgery) up to first flatus (up to Day 10 postsurgery)
Observed Plasma Concentration of TAK-954 at the End of Infusion on Day 1
Time frame: Day 1 (surgery): postinfusion